Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?

Group 1 - Acrivon Therapeutics, Inc. (ACRV) is currently outperforming its Medical sector peers with a year-to-date gain of approximately 48.6%, compared to the average gain of 5.3% for Medical stocks [2][3] - The Zacks Consensus Estimate for ACRV's full-year earnings has increased by 17% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [2] - Acrivon Therapeutics, Inc. holds a Zacks Rank of 2 (Buy), suggesting it has favorable characteristics for potential outperformance in the market [1] Group 2 - Acrivon Therapeutics, Inc. is part of the Medical - Drugs industry, which consists of 185 stocks and currently ranks 83 in the Zacks Industry Rank; this industry has seen an average loss of 7.2% year-to-date [3] - In contrast, Hims & Hers Health, Inc. (HIMS), another stock in the Medical sector, has achieved a year-to-date return of 134% and has a Zacks Rank of 1 (Strong Buy) [2][3] - The Medical Info Systems industry, which includes Hims & Hers Health, has 43 stocks and is ranked 72, with an average decline of 19.7% since the beginning of the year [3]